Brief: Paion Says Hana Pharm Gets Market Approval For Byfavo In Procedural Sedation In South Korea
Aug 31 (Reuters) - PAION AG PA8G.DE :
* HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO
(REMIMAZOLAM) IN
PROCEDURAL SEDATION IN SOUTH KOREA
Source text for Eikon: ID:nEQ5VY3b1a
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022